IBOV 172,140.47 ▲ 0.65% IPSA 11,505.53 ▲ 1.47% IPC MEX 66,101.04 ▲ 0.57% MERVAL 2,990,152 ▲ 2.64% COLCAP 2,492.22 ▲ 1.34% BVL PERÚ 60,222.25 ▼ 0.22% USD/BRL5.15▲ 0.30% USD/MXN16.96▲ 0.30% USD/CLP911.82▼ 0.35% USD/COP3,056▲ 0.42% USD/PEN3.35▼ 0.07% USD/ARS1,509▲ 0.63% USD/UYU40.18▼ 0.03% USD/PYG5,989▼ 0.11% USD/BOB11.44▲ 0.09% USD/DOP58.07▼ 0.99% USD/CRC446.05▼ 0.89% USD/GTQ7.62▼ 0.04% USD/HNL26.82▲ 0.02% USD/NIO36.62— 0.00% USD/VES782.70▲ 0.48% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.72▲ 0.25% EUR/BRL6.01▲ 0.15% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 172,140.47 ▲ 0.65% IPSA 11,505.53 ▲ 1.47% IPC MEX 66,101.04 ▲ 0.57% MERVAL 2,990,152 ▲ 2.64% COLCAP 2,492.22 ▲ 1.34% BVL PERÚ 60,222.25 ▼ 0.22% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 24, 2026

Brazil Covid-19

Rio de Janeiro to begin today vaccinating children 4 years and older against Covid

By · July 15, 2022 · 4 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – In Rio de Janeiro, 4-year-old children will be vaccinated against Covid-19 starting Friday (15).

The vaccination period for this age group runs through July 19, except for Sunday, July 17.

The declaration came one day after Anvisa (National Health Regulator) approved the use of CoronaVac in children ages 3 to 5.

(Dr. Ryan Cole: Giving mRNA Covid Vaccines to Children Is All Harm, All Risk, Zero Benefit)

The measure was approved unanimously. The vaccine formulation for children ages 3 to 5 years is the same as for adults, with an average interval of 28 days between the first and second doses. With this decision, CoronaVac is Brazil’s first Covid-19 vaccine approved for children in this age group.

Vaccination of children 3 years and older begins the following week, July 20, and continues until July 23.

OTHER STATES ARE WAITING

The Brazilian states of São Paulo, Minas Gerais, Amazonas, Amapá, Ceará, Rio Grande do Norte, Acre, Pernambuco, Espirito Santo, and Alagoas have informed that they will wait for the Ministry of Health to define the beginning of vaccination for children 3 years old and older. The other states have not yet pronounced themselves about the vaccination of this age group.

In an interview with the G1 portal, Health Minister Marcelo Queiroga said that the folder’s Technical Chamber will evaluate until Monday the Anvisa approval data. He also said he will meet with the Butantan Institute, which manufactures Coronavac in Brazil, about the availability of doses.

After the approval, Butantan announced that it had asked the Ministry to include the vaccine in the PNI for children aged 3 to 5 years. The Secretary of Health of São Paulo, Jean Gorinchteyn, told the newspaper Estadão that the Butantan does not rule out the possibility of importing the doses of Coronavac from China for the speed of vaccination of the new public.

Unlike in neighboring Uruguay, where a court has suspended Covid vaccination of toddlers with Pfizer injections, which uses the highly controversial mRNA technology, Brazil works with CoronaVac, which does not employ the mRNA technology but the traditional inactivated aluminum hydroxide-adjuvanted technology.

WHY ARE MRNA VACCINES SO CONTROVERSIAL?

Previous efforts to create such a vaccine have resulted in antibody-dependent enhancement (ADE), in which immunization makes matters worse, not better.

We never noticed that the Pfizer etc., studies were supposed to tell their study participants that ADE was a possibility and would appear as the vaccine waned. They even wrote in their official papers that all people should be advised of this possibility to have appropriate informed consent.

But people were not told any such thing before being given their shot. And the reason the booster is so urgently being considered? Because, yes, the vaccine is waning. And yes, people are getting sick. Not just a little ill, but VERY sick.

RT
Ask Rio Times
Latin American culture, food and life.
Open the full Ask Rio Times →
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →

Even before ADE, however, the side effects reported for this vaccine are many times more than reported for all other vaccines put together over the past few decades. We reached that milestone within a half year of the vaccine rollout.

Now, it’s one thing when people die from the disease. And it’s another thing when they die because appropriate early treatment is suppressed.

After all, it would interfere with vaccine permissions. And it’s still another thing when people are encouraged to say that deaths from the vaccine are okay because, numerically, they aren’t such a high percent.

WHAT IS THE DIFFERENCE BETWEEN TRADITIONAL AND MRNA VACCINES?

Messenger RNA (mRNA) vaccines work differently compared to other vaccines. For example, other vaccines may contain weakened or dead germs (or part of the germ). This trains your immune system to quickly recognize and fight the germ if you’re exposed to it in the future.

But mRNA vaccines don’t contain germs at all. Instead, they contain something called mRNA. Your body has its own mRNA inside of cells. Think of mRNA as a set of instructions. Your cells use these instructions to make proteins that your body needs. But the mRNA in vaccines can also be used to instruct your cells to make certain proteins.

For example, the vaccine mRNA might contain the code to make part of a germ (called an antigen). When delivered to your cells, it instructs them to make the antigen. This is what triggers your immune system to respond to an mRNA vaccine.

In the case of the COVID-19 vaccines, your cells are instructed to make part of SARS-CoV-2 (the virus that causes COVID-19). This is what triggers your immune system and creates protection against the virus if you encounter it in the future.

 

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.